Post hoc win ratio analysis of two phase 3 trials (1872 patients with COPD and type 2 inflammation): dupilumab vs placebo gave a win ratio of 1.31 (95% CI 1.15-1.48) across death, hospitalisation, exacerbations, lung function and symptoms.
Secondary analysisn = 1,872
Ramakrishnan et al. Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS (Two Pivotal Studies to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-Severe COPD With Type 2 Inflammation)